Therefore, to provide a comprehensive evaluation of PD-L1 expression in metastatic melanoma, the authors proposed the assessment of PD-L1 staining to include both PD-L1 expressed by tumor cells (TCs) and combined analyses of TCs and immune cells (ICs) using the MEL score or the CPS. This evidence concerns the gene CD274 and metastatic melanoma.